Many researchers, however, pointout that the 30-day stroke and death rate in stent patients was significantly higher (4.8%) than that of surgery patients (2.6%).
Indeed, some researchers are quick to pointout differences in the clinical trials being run by AstraZeneca on one hand and OSI and Genentech on the other for what are seen by many as similar drugs.
Researcherspointout that this quest for realism does not normally extend to showing the realistic effects of smoking such as breathlessness, wheezing and ill health.